---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011778"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2025-08-27T23:59:59+00:00"
generated_at: "2026-05-17T09:37:25.434139+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth

## Summary
- Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).
- FY net sales $1,296.2M (+27%), adj. EBITDA $183.7M (+65%), adj. diluted EPS $2.09 (+76%).
- Zoetis MFA portfolio contributed $94.5M incremental revenue in Q4 and $208.2M for full year.
- FY2026 guidance: net sales $1.43-1.48B, adj. EBITDA $225-235M (25% growth), adj. EPS $2.52-2.70.
- Gross leverage 3.1x as of June 30, 2025; free cash flow $41.8M for the year.

## SEC filing metadata
- accession: 0001558370-25-011778
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2025-08-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/0001558370-25-011778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/pahc-20250827x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011778
- JSON: https://secwatch.observer/filing/0001558370-25-011778.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.